Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up - Should You Buy?

Key Points

• Structure Therapeutics (NASDAQ:GPCR) shares experienced a significant gap up, opening at $21.29 after a previous close of $19.96, but last traded at $19.37.
• Recent analyst evaluations revealed new price targets, with HC Wainwright reducing their target from $75.00 to $60.00 while maintaining a "buy" rating, contributing to an average target of $75.71 among analysts.
• The company reported a loss of ($0.36) earnings per share for its latest quarterly earnings, missing the consensus estimate by ($0.08).

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report)'s share price gapped up prior to trading on Tuesday . The stock had previously closed at $19.96, but opened at $21.29. Structure Therapeutics shares last traded at $19.37, with a volume of 166,042 shares traded.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Guggenheim decreased their price objective on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a research report on Thursday, August 7th. Cantor Fitzgerald restated an "overweight" rating and issued a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday, June 23rd. JMP Securities decreased their price objective on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 7th. HC Wainwright decreased their price objective on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a research report on Thursday, August 7th. Finally, Citigroup assumed coverage on shares of Structure Therapeutics in a research report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price objective on the stock. Eight equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Structure Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $75.71.

Structure Therapeutics Stock Down 0.3%

The firm's 50-day moving average is $19.28 and its 200-day moving average is $21.23. The company has a market cap of $1.11 billion, a PE ratio of -18.81 and a beta of -1.89.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08). As a group, equities research analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC grew its stake in shares of Structure Therapeutics by 5.1% in the 4th quarter. Janus Henderson Group PLC now owns 4,159,888 shares of the company's stock worth $112,816,000 after buying an additional 203,010 shares in the last quarter. Deep Track Capital LP increased its holdings in shares of Structure Therapeutics by 129.4% in the 4th quarter. Deep Track Capital LP now owns 2,800,000 shares of the company's stock worth $75,936,000 after buying an additional 1,579,492 shares during the last quarter. Vestal Point Capital LP increased its holdings in shares of Structure Therapeutics by 3.7% in the 1st quarter. Vestal Point Capital LP now owns 1,788,990 shares of the company's stock worth $30,967,000 after buying an additional 63,990 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Structure Therapeutics by 7.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,588,198 shares of the company's stock worth $32,939,000 after buying an additional 106,389 shares during the last quarter. Finally, Orbimed Advisors LLC increased its holdings in shares of Structure Therapeutics by 49.5% in the 2nd quarter. Orbimed Advisors LLC now owns 1,199,300 shares of the company's stock worth $24,873,000 after buying an additional 397,272 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.